» Articles » PMID: 18221492

Activation of Hepatocyte Growth Factor Activator Zymogen (pro-HGFA) by Human Kallikrein 1-related Peptidases

Overview
Journal FEBS J
Specialty Biochemistry
Date 2008 Jan 29
PMID 18221492
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocyte growth factor activator (HGFA) is a serine protease and a potent activator of prohepatocyte growth factor/scatter factor (pro-HGF/SF), a multifunctional growth factor that is critically involved in tissue morphogenesis, regeneration, and tumor progression. HGFA circulates as a zymogen (pro-HGFA) and is activated in response to tissue injury. Although thrombin is considered to be an activator of pro-HGFA, alternative pro-HGFA activation pathways in tumor microenvironments remain to be identified. In this study, we examined the effects of kallikrein 1-related peptidases (KLKs), a family of extracellular serine proteases, on the activation of pro-HGFA. Among the KLKs examined (KLK2, KLK3, KLK4 and KLK5), we identified KLK4 and KLK5 as novel activators of pro-HGFA. Using N-terminal sequencing, the cleavage site was identified as the normal processing site, Arg407-Ile408. The activation of pro-HGFA by KLK5 required a negatively charged substance such as dextran sulfate, whereas KLK4 could process pro-HGFA without dextran sulfate. KLK5 showed more efficient pro-HGFA processing than KLK4, and was expressed in 50% (13/25) of the tumor cell lines examined. HGFA processed by these KLKs efficiently activated pro-HGF/SF, and led to cellular scattering and invasion in vitro. The activities of both KLK4 and KLK5 were strongly inhibited by HGFA inhibitor type 1, an integral membrane Kunitz-type serine protease inhibitor that inhibits HGFA and other pro-HGF/SF-activating proteases. These data suggest that KLK4 and KLK5 mediate HGFA-induced activation of pro-HGF/SF within tumor tissue, which may thereafter trigger a series of events leading to tumor progression via the MET receptor.

Citing Articles

Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin.

Mahoney M, Helander J, Kooner A, Norman M, Damalanka V, De Bona P Protein Sci. 2024; 33(8):e5110.

PMID: 39073183 PMC: 11284329. DOI: 10.1002/pro.5110.


Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.

Jones V, Graves-Deal R, Cao Z, Bogatcheva G, Ramirez M, Harmych S Cell Mol Life Sci. 2024; 81(1):28.

PMID: 38212428 PMC: 10784391. DOI: 10.1007/s00018-023-05071-5.


HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis.

Sargsyan A, Doridot L, Hannou S, Tong W, Srinivasan H, Ivison R JCI Insight. 2022; 8(1).

PMID: 36413406 PMC: 9870088. DOI: 10.1172/jci.insight.153740.


Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Srinivasan S, Kryza T, Batra J, Clements J Nat Rev Cancer. 2022; 22(4):223-238.

PMID: 35102281 DOI: 10.1038/s41568-021-00436-z.


Ovulation sources coagulation protease cascade and hepatocyte growth factor to support physiological growth and malignant transformation.

Huang H, Chen P, Chu S, Lee M, Huang C, Chu T Neoplasia. 2021; 23(11):1123-1136.

PMID: 34688971 PMC: 8550993. DOI: 10.1016/j.neo.2021.09.006.